Search hospitals > Kentucky > Louisville
Norton Cancer Institute
Claim this profileLouisville, Kentucky 40202
Global Leader in Lymphoma
Global Leader in Skin Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
220 reported clinical trials
13 medical researchers
Summary
Norton Cancer Institute is a medical facility located in Louisville, Kentucky. This center is recognized for care of Lymphoma, Skin Cancer, Lung Cancer, Non-Small Cell Lung Cancer, T-Lymphoblastic Leukemia/Lymphoma and other specialties. Norton Cancer Institute is involved with conducting 220 clinical trials across 183 conditions. There are 13 research doctors associated with this hospital, such as John Hamm, MD, Don Stevens, MD, Jaspreet Grewal, MD, and Joseph Maly.Area of expertise
1Lymphoma
Global LeaderMYC positive
BCL2 positive
BCL6 positive
2Skin Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
John Hamm, MDNorton Cancer Institute6 years of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
27 reported clinical trials
46 drugs studied
Don Stevens, MDNorton Cancer Institute2 years of reported clinical research
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
26 reported clinical trials
46 drugs studied
Jaspreet Grewal, MDNorton Cancer Institute4 years of reported clinical research
Studies Skin Cancer
Studies Squamous Cell Carcinoma
10 reported clinical trials
15 drugs studied
Joseph MalyNorton Cancer Institute4 years of reported clinical research
Studies Lymphoma
Studies T-Lymphoblastic Leukemia/Lymphoma
9 reported clinical trials
19 drugs studied
Clinical Trials running at Norton Cancer Institute
Non-Hodgkin's Lymphoma
Multiple Myeloma
Lymphoma
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
B-Cell Lymphoma
Lung Cancer
Plasma Cell Neoplasm
Ovarian Cancer
Cervical Cancer
RNK05047
for Cancer
This trial tests RNK05047, a new drug, on patients with advanced solid tumors, including DLBCL. The drug is given regularly through an IV to find the safest and most effective dose.
Recruiting1 award Phase 1 & 2
REGN5837 + Odronextamab
for Aggressive B-Cell Lymphoma
The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab (called "study drugs"). The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects) * To find out how well the study drugs work against relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs)
Recruiting1 award Phase 1
Cema-cel
for B-Cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITYâ„¢ Investigational Use Only (IUO) MRD test, powered by PhasED-Seqâ„¢. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. The study is conducted in 2 consecutive parts that will be enrolled continuously. In Part A of the study, participants with MRD are randomized to one of two treatment arms or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide administered with or without the anti-CD52 monoclonal antibody, ALLO-647. Part A will culminate with the selection of the lymphodepletion regimen to advance to Part B. Part B will evaluate the selected lymphodepletion regimen followed by cema-cel as compared with observation.
Recruiting1 award Phase 25 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Norton Cancer Institute?
Norton Cancer Institute is a medical facility located in Louisville, Kentucky. This center is recognized for care of Lymphoma, Skin Cancer, Lung Cancer, Non-Small Cell Lung Cancer, T-Lymphoblastic Leukemia/Lymphoma and other specialties. Norton Cancer Institute is involved with conducting 220 clinical trials across 183 conditions. There are 13 research doctors associated with this hospital, such as John Hamm, MD, Don Stevens, MD, Jaspreet Grewal, MD, and Joseph Maly.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.